Business Description
BridgeBio Pharma Inc
NAICS : 325412
SIC : 2834
ISIN : US10806X1028
Description
Financial Strength
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.25 | |||||
Equity-to-Asset | -2.48 | |||||
Debt-to-Equity | -1.29 | |||||
Debt-to-EBITDA | -3.08 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -7.8 | |||||
Beneish M-Score | -5.66 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -6.6 | |||||
3-Year EBITDA Growth Rate | 4.3 | |||||
3-Year EPS without NRI Growth Rate | -1.7 | |||||
3-Year FCF Growth Rate | 2 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 45.43 | |||||
9-Day RSI | 39.62 | |||||
14-Day RSI | 38.25 | |||||
6-1 Month Momentum % | 17.69 | |||||
12-1 Month Momentum % | 77.58 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.32 | |||||
Quick Ratio | 3.32 | |||||
Cash Ratio | 3.02 | |||||
Days Payable | 1033.67 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.5 | |||||
Shareholder Yield % | -9.91 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 73.71 | |||||
Operating Margin % | -6443.56 | |||||
Net Margin % | -6913.92 | |||||
FCF Margin % | -5676.26 | |||||
ROA % | -108.88 | |||||
ROIC % | -519.36 | |||||
ROC (Joel Greenblatt) % | -2513.15 | |||||
ROCE % | -120.38 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 439.12 | |||||
EV-to-EBIT | -10.35 | |||||
EV-to-Forward-EBIT | -10.14 | |||||
EV-to-EBITDA | -10.47 | |||||
EV-to-Forward-EBITDA | -10.24 | |||||
EV-to-Revenue | 636.55 | |||||
EV-to-Forward-Revenue | 549.94 | |||||
EV-to-FCF | -11.19 | |||||
Earnings Yield (Greenblatt) % | -9.66 | |||||
FCF Yield % | -11.46 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
BridgeBio Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 8.653 | ||
EPS (TTM) (€) | -3.656 | ||
Beta | 1.41 | ||
Volatility % | 115.67 | ||
14-Day RSI | 38.25 | ||
14-Day ATR (€) | 0.740707 | ||
20-Day SMA (€) | 25.1655 | ||
12-1 Month Momentum % | 77.58 | ||
52-Week Range (€) | 11.7 - 39.72 | ||
Shares Outstanding (Mil) | 184.45 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
BridgeBio Pharma Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
BridgeBio Pharma Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
BridgeBio Pharma Inc Frequently Asked Questions
What is BridgeBio Pharma Inc(FRA:2CL)'s stock price today?
When is next earnings date of BridgeBio Pharma Inc(FRA:2CL)?
Does BridgeBio Pharma Inc(FRA:2CL) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |